{"protocolSection": {"identificationModule": {"nctId": "NCT01061333", "orgStudyIdInfo": {"id": "0000-176"}, "secondaryIdInfos": [{"id": "2010_507", "type": "OTHER", "domain": "Merck"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "Early Airway Response to Allergen in Asthmatics (MK-0000-176)", "officialTitle": "A Two-Part, Randomized, Placebo-Controlled, Crossover Trial to Evaluate the Differential Effects of Inhaled Nedocromil, Oral Montelukast, and Inhaled Mometasone on Markers of the Early Airway Response to Allergen in Asthmatics"}, "statusModule": {"statusVerifiedDate": "2015-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-06"}, "primaryCompletionDateStruct": {"date": "2011-02", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-02-01", "studyFirstSubmitQcDate": "2010-02-02", "studyFirstPostDateStruct": {"date": "2010-02-03", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2012-04-26", "resultsFirstSubmitQcDate": "2012-04-26", "resultsFirstPostDateStruct": {"date": "2012-05-28", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-09-03", "lastUpdatePostDateStruct": {"date": "2015-09-04", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study will assess the Early Airway Response (EAR) associated change in forced expiratory volume in one second (FEV1) and plasma 9\u03b1-11\u00df-PGF2 ('9P') after single dose pretreatment of nedocromil, montelukast, and mometasone."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 16, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo", "type": "EXPERIMENTAL", "description": "Placebo", "interventionNames": ["Drug: Placebo"]}, {"label": "Montelukast", "type": "EXPERIMENTAL", "description": "Montelukast", "interventionNames": ["Drug: Comparator: Montelukast"]}, {"label": "Nedocromil", "type": "EXPERIMENTAL", "description": "Nedocromil", "interventionNames": ["Drug: Nedocromil"]}, {"label": "Mometasone", "type": "EXPERIMENTAL", "description": "Mometasone", "interventionNames": ["Drug: Comparator: Mometasone"]}], "interventions": [{"type": "DRUG", "name": "Nedocromil", "description": "Nedocromil 4 mg, as metered dose inhaler 1 hour prior to allergen challenge", "armGroupLabels": ["Nedocromil"]}, {"type": "DRUG", "name": "Comparator: Montelukast", "description": "Montelukast single 10 mg tablet administered 2 hours prior to allergen challenge", "armGroupLabels": ["Montelukast"], "otherNames": ["Singulair"]}, {"type": "DRUG", "name": "Comparator: Mometasone", "description": "Mometasone furoate 400 mcg by twisthaler, administered 2 hours prior to allergen challenge", "armGroupLabels": ["Mometasone"]}, {"type": "DRUG", "name": "Placebo", "description": "Mometasone placebo twisthaler, Nedocromil placebo metered dose inhaler, Montelukast placebo tablet", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Forced Expiratory Volume in 1 Second (FEV1)", "description": "Maximal percent drop in FEV1 at 20 minutes post allergen challenge", "timeFrame": "Pre-allergen challenge and 20 minutes after allergen challenge"}, {"measure": "Change in Plasma 9\u03b1-11\u03b2-PGF2 (9P) at 5 Minutes", "description": "Fold change over baseline of plasma 9P at 5 minutes post-allergen challenge", "timeFrame": "Pre-allergen challenge and 5 minutes post allergen challenge"}, {"measure": "Change in Plasma 9P at 20 Minutes", "description": "Fold change over baseline of plasma 9P at 20 minutes post-allergen challenge", "timeFrame": "Pre-allergen challenge and 20 minutes post allergen challenge"}], "secondaryOutcomes": [{"measure": "Allergen-induced Changes in Urinary 9P", "description": "Fold change over baseline in Urinary 9P at 2 hours post allergen challenge", "timeFrame": "Baseline and 2 hours post allergen challenge"}, {"measure": "Allergen-induced Changes in Urinary Leukotriene (LT) E4", "description": "Fold change over baseline in urinary LTE4 at 2 hours post-allergen challenge", "timeFrame": "Baseline and 2 hours post allergen challenge"}, {"measure": "Allergen-induced Concentrations of Sputum LTC4", "description": "Concentrations of LTC4 in sputum at 2 hours post-allergen challenge", "timeFrame": "2 hours post allergen challenge"}, {"measure": "Allergen-induced Concentrations of Sputum LTD4", "description": "Concentrations of LTD4 in sputum at 2 hours post-allergen challenge", "timeFrame": "2 hours post allergen challenge"}, {"measure": "Allergen-induced Concentrations of Sputum LTE4", "description": "Concentrations of LTE4 in sputum at 2 hours post-allergen challenge", "timeFrame": "2 hours post allergen challenge"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* History of mild to moderate Asthma\n* In good general health (except for asthma)\n* Stable and free of respiratory infection\n* Nonsmoker\n* Females highly unlikely to conceive (surgically sterilized, postmenopausal, or agrees to use 2 acceptable methods of birth control)\n\nExclusion Criteria:\n\n* Nursing mother\n* Recent or ongoing upper or lower respiratory tract infection\n* Unable to refrain from or anticipates the use of any prescription and non-prescription drugs\n* Consumes excessive amounts of alcohol or caffeine\n* History of stroke, chronic seizures, or major neurological disorder\n* History of cancer\n* Received a vaccination within the past 3 weeks", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "55 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Placebo-Montelukast-Nedocromil-Mometasone", "description": "Over the course of four 3-day treatment regimens, participants received a single dose of each drug starting with placebo, crossover of nedocromil or montelukast, crossover of nedocromil or montelukast, ending with mometasone; with a 20-day washout between each of the four treatment periods."}, {"id": "FG001", "title": "Placebo-Nedocromil-Montelukast-Mometasone", "description": "Over the course of four 3-day treatment regimens, participants received a single dose of each drug starting with placebo, crossover of nedocromil or montelukast, crossover of nedocromil or montelukast, ending with mometasone; with a 20-day washout between each of the four treatment periods."}], "periods": [{"title": "Period 1: Placebo Run-in", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "8"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "8"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Period 2: 20-day Washout", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "8"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "8"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Period 3: Nedocromil-Montelukast X-over", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "8"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "8"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Period 4: 20-day Washout", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "8"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Discontinued by Study Team", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}, {"title": "Period 5: Nedocromil-Montelukast X-over", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Period 6: 20-day Washout", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Period 7: Mometasone", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "All Participants", "description": "Over the course of four 3-day treatment regimens, participants received a single dose of each drug starting with placebo, nedocromil or montelukast, nedocromil or montelukast, ending with mometasone; with a 20-day washout between each of the four treatment periods."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "16"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "31.94", "spread": "7.47"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "4"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "12"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Forced Expiratory Volume in 1 Second (FEV1)", "description": "Maximal percent drop in FEV1 at 20 minutes post allergen challenge", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage drop in FEV1", "timeFrame": "Pre-allergen challenge and 20 minutes after allergen challenge", "groups": [{"id": "OG000", "title": "Placebo", "description": "Nedocromil placebo metered dose inhaler, montelukast placebo tablet, mometasone placebo twisthaler"}, {"id": "OG001", "title": "Nedocromil", "description": "Nedocromil 4 mg, administered by metered dose inhaler, 1 hour prior to allergen challenge"}, {"id": "OG002", "title": "Montelukast", "description": "Montelukast 10 mg, administered in a single tablet, 2 hours prior to allergen challenge"}, {"id": "OG003", "title": "Mometasone", "description": "Mometasone furoate 400 mcg, administered by twisthaler, 2 hours prior to allergen challenge"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "15"}, {"groupId": "OG003", "value": "15"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-24.66", "spread": "10.72"}, {"groupId": "OG001", "value": "-8.44", "spread": "6.15"}, {"groupId": "OG002", "value": "-9.15", "spread": "6.96"}, {"groupId": "OG003", "value": "-16.17", "spread": "11.01"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "p-value not adjusted for simultaneous multiple comparisons", "statisticalMethod": "ANCOVA", "paramType": "Difference in LS mean", "paramValue": "16.22", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "10.74", "ciUpperLimit": "21.69"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0001", "pValueComment": "p-value not adjusted for simultaneous multiple comparisons", "statisticalMethod": "ANCOVA", "paramType": "Difference in LS Mean", "paramValue": "15.51", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "10.00", "ciUpperLimit": "21.02"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0432", "pValueComment": "p-value not adjusted for simultaneous multiple comparisons", "statisticalMethod": "ANCOVA", "paramType": "Difference in LS Mean", "paramValue": "8.49", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.78", "ciUpperLimit": "15.20"}]}, {"type": "PRIMARY", "title": "Change in Plasma 9\u03b1-11\u03b2-PGF2 (9P) at 5 Minutes", "description": "Fold change over baseline of plasma 9P at 5 minutes post-allergen challenge", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Fold change over baseline", "timeFrame": "Pre-allergen challenge and 5 minutes post allergen challenge", "groups": [{"id": "OG000", "title": "Placebo", "description": "Nedocromil placebo metered dose inhaler, Montelukast placebo tablet, Mometasone placebo twisthaler"}, {"id": "OG001", "title": "Nedocromil", "description": "Nedocromil 4 mg, administered by metered dose inhaler, 1 hour prior to allergen challenge"}, {"id": "OG002", "title": "Montelukast", "description": "Montelukast 10 mg, administered in a single tablet, 2 hours prior to allergen challenge"}, {"id": "OG003", "title": "Mometasone", "description": "Mometasone furoate 400 mcg, administered by twisthaler, 2 hours prior to allergen challenge"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "15"}, {"groupId": "OG003", "value": "15"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.77", "spread": "0.21"}, {"groupId": "OG001", "value": "0.97", "spread": "0.17"}, {"groupId": "OG002", "value": "1.08", "spread": "0.44"}, {"groupId": "OG003", "value": "1.00", "spread": "0.35"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0430", "pValueComment": "p-Value not adjusted for simultaneous multiple comparisons", "statisticalMethod": "ANCOVA", "statisticalComment": "concentrations evaluated at log scale", "paramType": "Geom. Mean Ratio of fold over baseline", "paramValue": "1.27", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.05", "ciUpperLimit": "1.54"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0100", "pValueComment": "p-Value not adjusted for simultaneous multiple comparisons", "statisticalMethod": "ANCOVA", "statisticalComment": "concentrations evaluated at log scale", "paramType": "Geom. Mean Ratio of fold over baseline", "paramValue": "1.41", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.15", "ciUpperLimit": "1.72"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0860", "pValueComment": "p-Value not adjusted for simultaneous multiple comparisons", "statisticalMethod": "ANCOVA", "statisticalComment": "concentrations evaluated at log scale", "paramType": "Geom. Mean Ratio of fold over baseline", "paramValue": "1.30", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.01", "ciUpperLimit": "1.67"}]}, {"type": "PRIMARY", "title": "Change in Plasma 9P at 20 Minutes", "description": "Fold change over baseline of plasma 9P at 20 minutes post-allergen challenge", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Fold change over baseline", "timeFrame": "Pre-allergen challenge and 20 minutes post allergen challenge", "groups": [{"id": "OG000", "title": "Placebo", "description": "Nedocromil placebo metered dose inhaler, montelukast placebo tablet, mometasone placebo twisthaler"}, {"id": "OG001", "title": "Nedocromil", "description": "Nedocromil 4 mg, administered by metered dose inhaler, 1 hour prior to allergen challenge"}, {"id": "OG002", "title": "Montelukast", "description": "Montelukast 10 mg, administered in a single tablet, 2 hours prior to allergen challenge"}, {"id": "OG003", "title": "Mometasone", "description": "Mometasone furoate 400 mcg, administered by twisthaler, 2 hours prior to allergen challenge"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "15"}, {"groupId": "OG003", "value": "15"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.22", "spread": "0.31"}, {"groupId": "OG001", "value": "0.72", "spread": "0.25"}, {"groupId": "OG002", "value": "0.72", "spread": "0.21"}, {"groupId": "OG003", "value": "1.06", "spread": "0.40"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "p-Value not adjusted for simultaneous multiple comparisons", "statisticalMethod": "ANCOVA", "statisticalComment": "concentrations evaluated at log scale", "paramType": "Geom. Mean Ratio of fold over baseline", "paramValue": "0.59", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.50", "ciUpperLimit": "0.70"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "p-Value not adjusted for simultaneous multiple comparisons", "statisticalMethod": "ANCOVA", "statisticalComment": "concentrations evaluated at log scale", "paramType": "Geom. Mean Ratio of fold over baseline", "paramValue": "0.59", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.49", "ciUpperLimit": "0.70"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2679", "pValueComment": "p-Value not adjusted for simultaneous multiple comparisons", "statisticalMethod": "ANCOVA", "statisticalComment": "concentrations evaluated at log scale", "paramType": "Geom. Mean Ratio of fold over baseline", "paramValue": "0.87", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.69", "ciUpperLimit": "1.08"}]}, {"type": "SECONDARY", "title": "Allergen-induced Changes in Urinary 9P", "description": "Fold change over baseline in Urinary 9P at 2 hours post allergen challenge", "populationDescription": "Only participants with baseline values were analyzed", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Fold change over baseline", "timeFrame": "Baseline and 2 hours post allergen challenge", "groups": [{"id": "OG000", "title": "Placebo", "description": "Nedocromil placebo metered dose inhaler, montelukast placebo tablet, mometasone placebo twisthaler"}, {"id": "OG001", "title": "Nedocromil", "description": "Nedocromil 4 mg, administered by metered dose inhaler, 1 hour prior to allergen challenge"}, {"id": "OG002", "title": "Montelukast", "description": "Montelukast 10 mg, administered in a single tablet, 2 hours prior to allergen challenge"}, {"id": "OG003", "title": "Mometasone", "description": "Mometasone furoate 400 mcg, administered by twisthaler, 2 hours prior to allergen challenge"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "14"}, {"groupId": "OG003", "value": "13"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.54", "spread": "2.43"}, {"groupId": "OG001", "value": "1.39", "spread": "2.54"}, {"groupId": "OG002", "value": "1.45", "spread": "4.22"}, {"groupId": "OG003", "value": "1.40", "spread": "2.24"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7622", "pValueComment": "p-Value not adjusted for simultaneous multiple comparisons", "statisticalMethod": "ANCOVA", "statisticalComment": "concentrations evaluated at log scale", "paramType": "Geom. Mean Ratio of fold over baseline", "paramValue": "0.90", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.51", "ciUpperLimit": "1.59"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.8468", "pValueComment": "p-Value not adjusted for simultaneous multiple comparisons", "statisticalMethod": "ANCOVA", "statisticalComment": "concentrations evaluated on log scale", "paramType": "Geom. Mean Ratio of fold over baseline", "paramValue": "0.94", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.53", "ciUpperLimit": "1.65"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.6140", "pValueComment": "p-Value not adjusted for simultaneous multiple comparisons", "statisticalMethod": "ANCOVA", "statisticalComment": "concentrations evaluated at log scale", "paramType": "Geom. Mean Ratio of fold over baseline", "paramValue": "0.91", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.65", "ciUpperLimit": "1.26"}]}, {"type": "SECONDARY", "title": "Allergen-induced Changes in Urinary Leukotriene (LT) E4", "description": "Fold change over baseline in urinary LTE4 at 2 hours post-allergen challenge", "populationDescription": "Only participants with baseline values were analyzed", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Fold change over baseline", "timeFrame": "Baseline and 2 hours post allergen challenge", "groups": [{"id": "OG000", "title": "Placebo", "description": "Nedocromil placebo metered dose inhaler, montelukast placebo tablet, mometasone placebo twisthaler"}, {"id": "OG001", "title": "Nedocromil", "description": "Nedocromil 4 mg, administered by metered dose inhaler, 1 hour prior to allergen challenge"}, {"id": "OG002", "title": "Montelukast", "description": "Montelukast 10 mg, administered in a single tablet, 2 hours prior to allergen challenge"}, {"id": "OG003", "title": "Mometasone", "description": "Mometasone furoate 400 mcg, administered by twisthaler, 2 hours prior to allergen challenge"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "14"}, {"groupId": "OG003", "value": "13"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.77", "spread": "1.09"}, {"groupId": "OG001", "value": "1.19", "spread": "1.31"}, {"groupId": "OG002", "value": "1.40", "spread": "1.52"}, {"groupId": "OG003", "value": "1.62", "spread": "1.35"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0006", "pValueComment": "p-Value not adjusted for simultaneous multiple comparisons", "statisticalMethod": "ANCOVA", "statisticalComment": "concentrations evaluated at log scale", "paramType": "Geom. Mean Ratio of fold over baseline", "paramValue": "0.67", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.57", "ciUpperLimit": "0.80"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0291", "pValueComment": "p-Value not adjusted for simultaneous multiple comparisons", "statisticalMethod": "ANCOVA", "statisticalComment": "concentrations evaluated at log scale", "paramType": "Geom. Mean Ratio of fold over baseline", "paramValue": "0.79", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.67", "ciUpperLimit": "0.94"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.3738", "pValueComment": "p-Value not adjusted for simultaneous multiple comparisons", "statisticalMethod": "ANCOVA", "statisticalComment": "concentrations evaluated at log scale", "paramType": "Geom. Mean Ratio of fold over baseline", "paramValue": "0.92", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.77", "ciUpperLimit": "1.08"}]}, {"type": "SECONDARY", "title": "Allergen-induced Concentrations of Sputum LTC4", "description": "Concentrations of LTC4 in sputum at 2 hours post-allergen challenge", "populationDescription": "Pre-imputation status. Missing data points were excluded and values below the lower limit of quantification (LLOQ) were included in the analysis with an assigned value of assay LLOQ.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/mL", "timeFrame": "2 hours post allergen challenge", "groups": [{"id": "OG000", "title": "Placebo", "description": "Nedocromil placebo metered dose inhaler, montelukast placebo tablet, mometasone placebo twisthaler"}, {"id": "OG001", "title": "Nedocromil", "description": "Nedocromil 4 mg, administered by metered dose inhaler, 1 hour prior to allergen challenge"}, {"id": "OG002", "title": "Montelukast", "description": "Montelukast 10 mg, administered in a single tablet, 2 hours prior to allergen challenge"}, {"id": "OG003", "title": "Mometasone", "description": "Mometasone furoate 400 mcg, administered by twisthaler, 2 hours prior to allergen challenge"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "14"}, {"groupId": "OG003", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "13.63", "spread": "8.22"}, {"groupId": "OG001", "value": "14.02", "spread": "12.53"}, {"groupId": "OG002", "value": "13.76", "spread": "5.45"}, {"groupId": "OG003", "value": "12.14", "spread": "6.94"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7501", "pValueComment": "p-Value not adjusted for simultaneous multiple comparisons", "statisticalMethod": "ANOVA", "statisticalComment": "concentrations evaluated at log scale", "paramType": "Geom. mean of fold change over Placebo", "paramValue": "1.03", "ciPctValue": "90", "ciLowerLimit": "0.88", "ciUpperLimit": "1.20"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.9410", "pValueComment": "p-Value not adjusted for simultaneous multiple comparisons", "statisticalMethod": "ANOVA", "statisticalComment": "concentrations evaluated at log scale", "paramType": "Geom. mean of fold change over Placebo", "paramValue": "1.01", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.81", "ciUpperLimit": "1.25"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1165", "pValueComment": "p-Value not adjusted for simultaneous multiple comparisons", "statisticalMethod": "ANOVA", "statisticalComment": "concentrations evaluated at log scale", "paramType": "Geom. mean of fold change over Placebo", "paramValue": "0.89", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.79", "ciUpperLimit": "1.01"}]}, {"type": "SECONDARY", "title": "Allergen-induced Concentrations of Sputum LTD4", "description": "Concentrations of LTD4 in sputum at 2 hours post-allergen challenge", "populationDescription": "Pre-imputation status. Missing data points were excluded and values below the lower limit of quantification (LLOQ) were included in the analysis with an assigned value of assay LLOQ.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/mL", "timeFrame": "2 hours post allergen challenge", "groups": [{"id": "OG000", "title": "Placebo", "description": "Nedocromil placebo metered dose inhaler, montelukast placebo tablet, mometasone placebo twisthaler"}, {"id": "OG001", "title": "Nedocromil", "description": "Nedocromil 4 mg, administered by metered dose inhaler, 1 hour prior to allergen challenge"}, {"id": "OG002", "title": "Montelukast", "description": "Montelukast 10 mg, administered in a single tablet, 2 hours prior to allergen challenge"}, {"id": "OG003", "title": "Mometasone", "description": "Mometasone furoate 400 mcg, administered by twisthaler, 2 hours prior to allergen challenge"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "14"}, {"groupId": "OG003", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "17.48", "spread": "15.20"}, {"groupId": "OG001", "value": "18.04", "spread": "31.13"}, {"groupId": "OG002", "value": "18.52", "spread": "9.22"}, {"groupId": "OG003", "value": "17.37", "spread": "36.91"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.8616", "pValueComment": "p-Value not adjusted for simultaneous multiple comparisons", "statisticalMethod": "ANOVA", "statisticalComment": "concentrations evaluated at log scale", "paramType": "Geom. mean of fold change over Placebo", "paramValue": "1.03", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.76", "ciUpperLimit": "1.41"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7512", "pValueComment": "p-Value not adjusted for simultaneous multiple comparisons", "statisticalMethod": "ANOVA", "statisticalComment": "concentrations evaluated at log scale", "paramType": "Geom. mean of fold change over Placebo", "paramValue": "1.06", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.77", "ciUpperLimit": "1.45"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.9723", "pValueComment": "p-Value not adjusted for simultaneous multiple comparisons", "statisticalMethod": "ANOVA", "statisticalComment": "concentrations evaluated at log scale", "paramType": "Geom. mean of fold change over Placebo", "paramValue": "0.99", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.72", "ciUpperLimit": "1.37"}]}, {"type": "SECONDARY", "title": "Allergen-induced Concentrations of Sputum LTE4", "description": "Concentrations of LTE4 in sputum at 2 hours post-allergen challenge", "populationDescription": "Pre-imputation status. Missing data points were excluded and values below the lower limit of quantification (LLOQ) were included in the analysis with an assigned value of assay LLOQ.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/mL", "timeFrame": "2 hours post allergen challenge", "groups": [{"id": "OG000", "title": "Placebo", "description": "Nedocromil placebo metered dose inhaler, montelukast placebo tablet, mometasone placebo twisthaler"}, {"id": "OG001", "title": "Nedocromil", "description": "Nedocromil 4 mg, administered by metered dose inhaler, 1 hour prior to allergen challenge"}, {"id": "OG002", "title": "Montelukast", "description": "Montelukast 10 mg, administered in a single tablet, 2 hours prior to allergen challenge"}, {"id": "OG003", "title": "Mometasone", "description": "Mometasone furoate 400 mcg, administered by twisthaler, 2 hours prior to allergen challenge"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "14"}, {"groupId": "OG003", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "115.5", "spread": "129.0"}, {"groupId": "OG001", "value": "149.8", "spread": "178.7"}, {"groupId": "OG002", "value": "181.3", "spread": "227.6"}, {"groupId": "OG003", "value": "140.3", "spread": "215.8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1983", "pValueComment": "p-Value not adjusted for simultaneous multiple comparisons", "statisticalMethod": "ANOVA", "statisticalComment": "concentrations evaluated at log scale", "paramType": "Geom. mean of fold change over Placebo", "paramValue": "1.30", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.92", "ciUpperLimit": "1.82"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0872", "pValueComment": "p-Value not adjusted for simultaneous multiple comparisons", "statisticalMethod": "ANOVA", "statisticalComment": "concentrations evaluated at log scale", "paramType": "Geom. mean of fold change over Placebo", "paramValue": "1.57", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.02", "ciUpperLimit": "2.42"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2499", "pValueComment": "p-Value not adjusted for simultaneous multiple comparisons", "statisticalMethod": "ANOVA", "statisticalComment": "concentrations evaluated at log scale", "paramType": "Geom. mean of fold change over Placebo", "paramValue": "1.22", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.91", "ciUpperLimit": "1.62"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Nedocromil placebo metered dose inhaler, montelukast placebo tablet, mometasone placebo twisthaler", "seriousNumAffected": 0, "seriousNumAtRisk": 16, "otherNumAffected": 5, "otherNumAtRisk": 16}, {"id": "EG001", "title": "Nedocromil", "description": "Nedocromil 4 mg, administered by metered dose inhaler, 1 hour prior to allergen challenge", "seriousNumAffected": 0, "seriousNumAtRisk": 16, "otherNumAffected": 4, "otherNumAtRisk": 16}, {"id": "EG002", "title": "Montelukast", "description": "Montelukast 10 mg, administered in a single tablet, 2 hours prior to allergen challenge", "seriousNumAffected": 0, "seriousNumAtRisk": 15, "otherNumAffected": 3, "otherNumAtRisk": 15}, {"id": "EG003", "title": "Mometasone", "description": "Mometasone furoate 400 mcg, administered by twisthaler, 2 hours prior to allergen challenge", "seriousNumAffected": 0, "seriousNumAtRisk": 15, "otherNumAffected": 0, "otherNumAtRisk": 15}], "otherEvents": [{"term": "Toothache", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (14.0)", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 15}]}, {"term": "Influenza Like Illness", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (14.0)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 15}]}, {"term": "Upper Respiratory Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (14.0)", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 15}]}, {"term": "Joint Sprain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (14.0)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 15}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (14.0)", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 15}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 15}]}, {"term": "Presyncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (14.0)", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 15}]}, {"term": "Rhinitis Allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (14.0)", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 15}]}, {"term": "Wheezing", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (14.0)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 15}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (14.0)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 15}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "For multicenter studies, subsequent to the multicenter publication, an investigator and colleagues may publish their data independently. Limitations of single site observations should always be described in such a manuscript. The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this study 60 days prior to submission. Any information identified by the SPONSOR as confidential must be deleted prior to submission."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["United Kingdom"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthmatic", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068656", "term": "Mometasone Furoate"}, {"id": "D000017835", "term": "Nedocromil"}, {"id": "C000093875", "term": "Montelukast"}], "ancestors": [{"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000020024", "term": "Leukotriene Antagonists"}, {"id": "D000006727", "term": "Hormone Antagonists"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000065694", "term": "Cytochrome P-450 CYP1A2 Inducers"}, {"id": "D000065693", "term": "Cytochrome P-450 Enzyme Inducers"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}, {"id": "D000082142", "term": "Mast Cell Stabilizers"}, {"id": "D000007155", "term": "Immunologic Factors"}], "browseLeaves": [{"id": "M290", "name": "Mometasone Furoate", "asFound": "At 3", "relevance": "HIGH"}, {"id": "M274108", "name": "Montelukast", "asFound": "Means", "relevance": "HIGH"}, {"id": "M20024", "name": "Nedocromil", "asFound": "TG01", "relevance": "HIGH"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M21876", "name": "Leukotriene Antagonists", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}]}}, "hasResults": true}